The price of GLP-1 drugs has attracted the scrutiny of lawmakers, and Novo Nordisk's chief executive Lars Fruergaard Jrgensen has agreed to appear at a Senate hearing next week to defend the pricing of the group's semaglutide-based therapies
When properly prescribed and administered, semaglutide can: Help patients lose about 15% of their body weight Regulate glucose levels and appetite Involve weekly injections designed for minimal discomfort Be an effective long-term weight loss solution (in conjunction with a healthy diet and active lifestyle)* While semaglutide injections have helped a number of patients combat obesity, please note that this treatment is not for everyone
For interruptions of 2 weeks or less at the same dose level, many providers consider it safe to resume at the same dose without re-escalation
Thats where NAD+ complements the physiology of GLP-1/GIP therapy
They Work On Separate Systems Without Much Risk Of Overlap HRT deals with sex hormones, while GLP-1 focuses on the gut and pancreas
Bottom line: If you mean fastest to meaningful, sustained weight loss, tirzepatide and semaglutide are strongest on published evidence
